Medical device M&A deals, led by Koninklijke Philips’ $2.8 billion acquisition of BioTelemetry, totaled $4.5 billion in Q4 2020, according to GlobalData’s deals database.
The value marked a decrease of 76.3 percent over the previous quarter and a drop of 30.3 percent when compared with the last four-quarter average, which stood at $6.46 billion.
Comparing cross border M&A deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $3.71 biollion. At the country level, the United States topped the list in terms of deal value at $3.44 billion.
In terms of volumes, Europe emerged as the top region for medical devices industry cross border M&A deals globally, followed by North America and then Asia-Pacific. The top country in terms of cross border M&A deals activity in Q4 2020 was the United States with 12 deals, followed by the UK with 10 and Canada with four.
In 2020, at the end of Q4 2020, cross border M&A deals worth $24.21 billion were announced globally in medical devices industry, marking an increase of 53.6 percent year on year.
The top five cross border M&A deals in medical devices industry accounted for 53.6 percent of the overall value during Q4 2020. The combined value of the top deals stood at $3.96 billion, against the overall value of $4.5 billion recorded for the quarter.
The top five medical devices industry cross border medical devices deals of Q4 2020 tracked by GlobalData were:
- Koninklijke Philips’ $2.8 billion acquisition of BioTelemetry
- The $410 million acquisition of Base Genomics by Exact Sciences
- Richter Gedeon Nyrt’s $263.5 million asset transaction with Janssen Pharmaceutica
- The $250 million acquisition of EmendoBio by AnGes
- Infratil’s acquisition of Qscan Group for $235.37 million.